What the study found
The study found descriptive post-marketing adverse event reporting patterns associated with casimersen in the United States FDA Adverse Event Reporting System (FAERS) database.
Why the authors say this matters
The authors say these findings may inform post-marketing pharmacovigilance activities and support hypothesis generation in future studies.
What the researchers tested
The researchers analyzed FAERS data for casimersen and summarized preferred term-level reporting distributions, affected organ system categories, and time-to-onset characteristics.
What worked and what didn't
The abstract reports that the study characterized reporting patterns and summarized distributions, organ system categories, and time-to-onset characteristics. It does not describe comparative effectiveness or identify specific adverse events in the provided text.
What to keep in mind
This is a descriptive pharmacovigilance study based on spontaneous reporting data. The abstract does not provide detailed limitations or causal conclusions.
Key points
- The study examined casimersen adverse event reports in the FDA Adverse Event Reporting System.
- It summarized preferred term-level reporting distributions and affected organ system categories.
- The analysis also included time-to-onset characteristics.
- The authors say the findings may help post-marketing pharmacovigilance and future hypothesis generation.
- The abstract does not report causal conclusions or detailed limitations.
Disclosure
- Research title:
- FAERS data show post-marketing adverse event patterns with casimersen
- Authors:
- Zhenghua Hao, Ke Jiang, Junfeng Zhang, Linmei Zhao
- Institutions:
- Shanxi Medical University, Second Hospital of Shanxi Medical University
- Publication date:
- 2026-02-26
- OpenAlex record:
- View
Get the weekly research newsletter
Stay current with peer-reviewed research without reading academic papers — one filtered digest, every Friday.